3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]2-methyl-phenyl}propionic acid | 847344-55-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]2-methyl-phenyl}propionic acid
• 英文别名: 3-{4-[3-(2-Benzoyl-4-ethyl-phenoxy)-butoxy]-2-methyl-phenyl}-propionic acid；3-[4-[3-(2-benzoyl-4-ethylphenoxy)butoxy]-2-methylphenyl]propanoic acid
• CAS: 847344-55-2
• 化学式: C₂₉H₃₂O₅
• 分子量: 460.57
• InChiKey: ONHBOWNRMGRYNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  34
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]2-methyl-phenyl}propionic acid 生成 (R)-3-(4-(3-(2-benzoyl-4-ethylphenoxy)butoxy)-2-methylphenyl)propanoic acid 、 (S)-3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]2-methyl-phenyl}propionic acid
  参考文献：
  名称：

  Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile

  摘要：

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-{4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.

  DOI：

  10.1021/jm060617c
• 作为产物：
  描述：

  3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]2-methyl-phenyl}propionic acid methyl ester 以 甲醇 为溶剂， 以provides the title compound (20 mg, 0.04 mmol, 100%)的产率得到3-{4-[3-(2-benzoyl-4-ethyl-phenoxy)-butoxy]2-methyl-phenyl}propionic acid
  参考文献：
  名称：

  Ppar modulators

  摘要：

  本发明涉及一种化合物I，或其药学上可接受的盐、溶剂化物、水合物或立体异构体，其在治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病方面具有用途，例如X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化以及其他与X综合征和心血管疾病有关的疾病。

  公开号：

  US20060257987A1

文献信息

• [EN] PPAR MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR ACTIVE DE LA PROLIFERATION DES PEROXYSOMES (PPAR)
  申请人：LILLY CO ELI

  公开号：WO2005019151A1

  公开（公告）日：2005-03-03

  The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种具有式I的化合物，或其药学上可接受的盐、溶剂合物、水合物或立体异构体，该化合物在治疗或预防由过氧化物酶体增殖物激活受体（PPAR）介导的疾病中具有用途，如X综合征、2型糖尿病、高血糖、高脂血症、肥胖、凝血障碍、高血压、动脉硬化以及与X综合征和心血管疾病相关的其他疾病。
• PPAR MODULATORS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1660428A1

  公开（公告）日：2006-05-31
• Design and Synthesis of Dual Peroxisome Proliferator-Activated Receptors γ and δ Agonists as Novel Euglycemic Agents with a Reduced Weight Gain Profile
  作者：Yanping Xu、Garret J. Etgen、Carol L. Broderick、Emily Canada、Isabel Gonzalez、Jason Lamar、Chahrzad Montrose-Rafizadeh、Brian A. Oldham、John J. Osborne、Chaoyu Xie、Qing Shi、Leonard L. Winneroski、Jeremy York、Nathan Yumibe、Richard Zink、Nathan Mantlo

  DOI：10.1021/jm060617c

  日期：2006.9.1

  The design and synthesis of the dual peroxisome proliferator-activated receptor ( PPAR) gamma/delta agonist (R)-3-4-[3-(4-chloro-2-phenoxyphenoxy)-butoxy]-2-ethyl-phenyl}-propionic acid (20) for the treatment of type 2 diabetes and associated dyslipidemia is described. The compound possesses a potent dual hPPAR gamma/delta agonist profile (IC50 = 19 nM/4 nM; EC50 = 102 nM/6 nM for hPPAR gamma and hPPAR delta, respectively). In preclinical models, the compound improves insulin sensitivity and reverses diabetic hyperglycemia with less weight gain at a given level of glucose control relative to rosiglitazone.
• Ppar modulators
  申请人：Gonzalez Valcarcel Isabel Cristina

  公开号：US20060257987A1

  公开（公告）日：2006-11-16

  The present invention is directed to a compound of formula I, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

  本发明涉及一种化合物I，或其药学上可接受的盐、溶剂化物、水合物或立体异构体，其在治疗或预防由过氧化物酶体增殖激活受体（PPAR）介导的疾病方面具有用途，例如X综合征、2型糖尿病、高血糖、高脂血症、肥胖症、凝血障碍、高血压、动脉硬化以及其他与X综合征和心血管疾病有关的疾病。